Nogalamycin is an anthracycline antibiotic produced from Streptomyces nogalater that 8 exerts its mechanism of action via inhibition of topoisomerase I. Nogalamycin has a unique 9 tetracyclic structure composed of a 7-O-glycosidically linked L-nogalose sugar and a C2-C5"-10 linked L-nogalamine residue that forms an epoxyoxacin ring. Nogalamycin was originally 11 developed as an anticancer agent in the 1970s, however, it exhibited dose-limiting 12 cardiotoxicity. Shortly after the discovery of nogalamycin, the semi-synthetic analogue 7-O-13 methylnogarol, or menogaril, was synthesized and exhibited a mild improvement in 14 cardiotoxicity and anticancer efficacy. Menogaril lacks the 7-O-L-nogalose moiety and functions 15 as a topoisomerase II inhibitor, like most anthracyclines, however this agent still proved too toxic 16 for clinical use. Our laboratory is developing a production platform for microbial synthesis of 17 novel nogalamycin analogs useful for treatment of human cancers or as antibiotics. Our initial 18 hypothesis is that overexpression of structural genes responsible for synthesis of TDP-19 deoxysugar and polyketide precursor substrates, respectively, will increase carbon flux towards 20 nogalamycin production. In this study, we have employed metabolic engineering to enhance 21 nogalamycin production in Streptomyces nogalater. In this work, we used an optimized soytone 22 glucose production medium to produce nogalamycin. We also overexpressed copies of 23 structural biosynthetic genes to bolster substrate precursor building blocks for nogalamycin nogalamycin (400 mg/L). This production platform will serve as the fundament for production of 29 nogalamycin analogues for future drug development efforts. 30 31 48 enhanced production titer of actinorhodin 3 . The deletion of zwf2 encoding glucose-6-49 phosphate dehydrogenase redirected carbon flux away from the pentose phosphate 50 pathway towards glycolysis and increased rates of synthesis for actinorhodin by 2-fold 51 and biomass 1.6-fold, respectively 3 . Notably, overexpression of accA2BE, encoding the 52 subunits of acetyl-CoA carboxylase, under the control of the ermE*p up promoter in S. 53 coelicolor M600 (SCP1 -SCP2 -) increased actinorhodin production 5-fold from 150 mg/L 54 to 750 mg/L. Recently, Zabala et al. conducted a precursor substrate engineering study 55 in a variety of actinomycetes to enhance production of several different polyketides, 56 including actinorhodin, nogalamycin, chromomycin A3, 8-demethyl-tetracenomycin C, 57 tetracenomycin C, elloramycin, and aclacinomycin 4 . The authors developed 58 overexpression constructs for the oviedomycin acetyl-CoA carboxylase (i.e. OvmGIH) to 59 enhance carbon flux of acetyl-CoA to malonyl-CoA (Figure 1) in the actinomycete 60 producer strains. Notably, overexpression of ovmGIH lead to a 943% increase in 61 actinorhodin production, however, the production titer of anthracyclines was enhanced 62 less than 1-fold via this strategy. For these pathways, this result suggests that 63 regulation of malonyl-CoA metabolism and polyketide biosynthesis might be 64 independently controlled. This observation motivated the present work to extend 65 metabolic engineering studies to include overexpression of polyketide synthase and 66 deoxysugar biosynthesis structural genes in the nogalamycin biosynthetic pathway. We 67 hypothesize that metabolic engineering of the mithramycin mtmDE genes encoding 68 TDP-D-glucose and TDP-D-glucose-4,6-dehydratase geneswith the snoa123 minimal 69 polyketide synthase could more effectively shift carbon flux towards nogalamycin 70 production.
production. First, overexpression of the TDP-glucose synthase and TDP-D-glucose-4,6-25 dehydratase enzymes (mtmDE) resulted in a 50% increase in nogalamycin production (160 26 mg/L) as compared to wildtype S. nogalater (100 mg/L). Secondly, overexpression of the 27 minimal polyketide synthase genes (snoa123) resulted in a fourfold production increase in 28 Introduction 32 Actinomycetes are industrially indispensable microorganisms that biosynthesize 33 chemicals ranging from antibiotics to antitumor agents and secrete hydrolytic enzymes 34 for the degradation of biochemical polymers. Since wildtype strains do not often exhibit 35 the production phenotype at industrial scale, strain improvement is required. The 36 isolation and characterization of industrial producing strains is accompanied by medium 37 optimization, exemplified by design of experiments (DOE) approaches such as one-38 factor-at-a-time (OFAT) or factorial design, to identify medium components that 39 augment production 1 . Though fermentation medium optimization can yield production 40 titer improvements of several-fold, rigorous strain improvement protocols are required to 41 enhance production to hundred milligram or gram per liter scales. Actinomycete strain 42 optimization programs have historically focused on random mutagenesis and high-43 throughput screening efforts, however, advances in actinomycete genome sequencing 44 and development of recombinant genetic tools have enabled the metabolic engineering 45 of actinomycetes for production of chemicals 2 .
Previously, Ryu et al. demonstrated that metabolic engineering of carbon flux in actinorhodin producer Streptomyces coelicolor M510 (SCP1 -SCP2 -ΔredD) dramatically for 3 days at 28⁰C until sporulation as described previously 16 Spores were inoculated 115 into 5 mL of tryptic soy broth medium (TSB) and grown for 2 days at 30⁰C to prepare a 116 seed culture. S. nogalater was transformed via intergeneric conjugation and E. coli 117 ET12567/pUZ8002 was used as a conjugation donor as previously described 17 To determine biomass production and nogalamycin titer of S. nogalater NRRL 152 3035 in a variety of production media, the wildtype strain was first grown in triplicate 50 153 mL GYM, NDYE, and SG liquid media shake flask fermentations for 4 days (Figure 2 ).
154
S. nogalater exhibited the highest biomass production and nogalamycin titer in SG liquid 155 media (120 mg/L and 17 gCDW/L), followed by NDYE media (80 mg/L and 15 156 gCDW/L), and last GYM media (20 mg/L and 12 gCDW/L) ( Figure 3 ). This experiment 157 established a baseline nogalamycin production titer in each production medium. Next, we supplemented each production medium with different carbon sources: 2% w/v 159 glucose, 2% v/v glycerol, 2% w/v maltose, and 2% w/v starch and different nitrogen 160 sources: 2% w/v soytone, 2% w/v tryptone, 2% w/v peptone, 2% w/v yeast extract. The 161 wildtype S. nogalater was grown in double triplicate 3 mL culture tube fermentations of 162 each type of medium with and without carbon source or nitrogen source 163 supplementation for 3 days (Figure 3 ). We compared the production of nogalamycin 164 between supplemented media and basal media and performed untailed T-test statistical 165 analysis to determine statistical significance.
166
In general, the culture tube fermentations exhibited lower production titers 167 overall, most likely due to poorer oxygenation. Supplementation of GYM media with 168 glucose, yeast extract, peptone, or soytone resulted in statistically significant increase of 169 nogalamycin production by 33% as compared to GYM media (60 mg/L, Figure 2 ).
170
Supplementation of NDYE with all carbon and nitrogen sources tested resulted in 171 statistically significant increase in production of nogalamycin of 1 to 4-fold (60 mg/L to 172 120 mg/L). Supplementation of SG media with glucose and glycerol lead to a 173 statistically significant 20% decrease in nogalamycin production titer. Supplementation 174 with other carbon and nitrogen sources increased production slightly, though the result 175 was not statistically significant. to determine potential rate-limiting steps of nogalamycin metabolism (Figure 4 ). First, fact that it lacks a readily accessible carbon or nitrogen source, and probably because 204 much of the carbon and nitrogen are directed towards biomass synthesis ( Figure 2) . 205 This result also demonstrates that Streptomyces nogalater is capable of using additional 206 carbon and nitrogen sources for polyketide biosynthesis. On the other hand, GYM 207 media experiments demonstrated a statistically significant increase in nogalamycin 208 production when they were supplemented with additional glucose, yeast extract, 209 peptone, or soytone. These experiments demonstrate that S. nogalater benefits from 210 additional supplementation with glucose, its preferred carbon source, and additional 211 nitrogen sources. Nutrient supplementation into SG liquid medium failed to increase 212 production of nogalamycin, and in two cases, addition of glucose and glycerol 213 decreased production. One possible explanation for this could be that additional glucose 214 supplementation is directed towards biomass production and not nogalamycin 215 production, which is reflected in the high biomass production of S. nogalater in SG liquid 216 medium (17 gCDW/L).
217
Most importantly, substrate precursor metabolic engineering was demonstrated 218 to further take advantage of additional nutrient supplementation in SG liquid medium.
219
When Streptomyces nogalater was transformed with empty plasmid vector, pWHM3, no 220 additional increase in nogalamycin production was observed. Engineering of mtmDE 221 resulted in a 50% increase in nogalamycin production to 160 mg/L when compared to 222 the control strain, most likely due to the increase of TDP-deoxysugar precursors in the Streptomyces nogalater was grown in GYM, NDYE, and SG liquid medium 
